Rakovina Therapeutics Inc. announced that the Company has been selected to join a three year USD 975,000 (CAD 1,297,000) research program funded by the St. Baldrick?s Foundation Martha?s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults. Rakovina Therapeutics will supply test compounds and support the project with technical personnel. Funding from the St. Baldrick?s Foundation will support pre-clinical IND-enabling research conducted at the University of British Columbia over the next 12 months.